JP2021520406A - Braf変異を有するがんのための組合せ治療 - Google Patents
Braf変異を有するがんのための組合せ治療 Download PDFInfo
- Publication number
- JP2021520406A JP2021520406A JP2021503193A JP2021503193A JP2021520406A JP 2021520406 A JP2021520406 A JP 2021520406A JP 2021503193 A JP2021503193 A JP 2021503193A JP 2021503193 A JP2021503193 A JP 2021503193A JP 2021520406 A JP2021520406 A JP 2021520406A
- Authority
- JP
- Japan
- Prior art keywords
- salt
- palbociclib
- cobimetinib
- osimertinib
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/082191 WO2019195959A1 (en) | 2018-04-08 | 2018-04-08 | Combination therapy for cancers with braf mutation |
| CNPCT/CN2018/082191 | 2018-04-08 | ||
| PCT/CN2019/081674 WO2019196764A1 (en) | 2018-04-08 | 2019-04-08 | Combination therapy for cancers with braf mutation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021520406A true JP2021520406A (ja) | 2021-08-19 |
| JP2021520406A5 JP2021520406A5 (cg-RX-API-DMAC7.html) | 2022-04-15 |
Family
ID=68163067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503193A Pending JP2021520406A (ja) | 2018-04-08 | 2019-04-08 | Braf変異を有するがんのための組合せ治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11753476B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3773719A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021520406A (cg-RX-API-DMAC7.html) |
| CN (2) | CN121313846A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019251124B2 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2019195959A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024516828A (ja) * | 2021-04-30 | 2024-04-17 | シティ・オブ・ホープ | がん治療のためのpcna阻害剤及びegfr阻害剤 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| WO2020036852A1 (en) | 2018-08-13 | 2020-02-20 | Beijing Percans Oncology Co. Ltd. | Biomarkers for cancer therapy |
| US11458149B1 (en) | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| BR112021024108A2 (pt) | 2019-05-31 | 2022-03-22 | Ikena Oncology Inc | Inibidores de tead e usos dos mesmos |
| WO2021068868A1 (en) * | 2019-10-09 | 2021-04-15 | Cothera Bioscience, Inc. | Combination therapy for cancers with kras mutation |
| CA3186465A1 (en) * | 2019-10-22 | 2021-04-29 | Chemistry Rx | Methods for treating congenital epidermal hyperplasia |
| BR112023014751A2 (pt) * | 2021-01-25 | 2023-10-03 | Ikena Oncology Inc | Combinação de um inibidor de tead de 3-(imidazol-4-il)-4-(amino)-benzenossulfonamida com um inibidor de egfr e/ou inibidor de mek para uso no tratamento de câncer de pulmão |
| EP4288057A4 (en) * | 2021-02-05 | 2025-03-12 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| CN115944625A (zh) * | 2022-09-05 | 2023-04-11 | 湖南灵康医疗科技有限公司 | 一种黑色素瘤治疗药物组合物及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012095505A1 (en) * | 2011-01-12 | 2012-07-19 | Boehringer Ingelheim International Gmbh | Anticancer therapy with dual aurora kinase / mek inhibitors |
| JP2013537544A (ja) * | 2010-08-17 | 2013-10-03 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗癌剤併用療法 |
| JP2015523397A (ja) * | 2012-07-26 | 2015-08-13 | ノバルティス アーゲー | Cdk4/6阻害剤およびb−raf阻害剤の組合せ医薬 |
| JP2017502013A (ja) * | 2013-12-20 | 2017-01-19 | バイオメッド バレー ディスカバリーズ,インコーポレイティド | Cdk阻害剤およびerk阻害剤の組み合わせを使用するがん処置 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965362A (en) | 1992-03-04 | 1999-10-12 | The Regents Of The University Of California | Comparative genomic hybridization (CGH) |
| HU221001B1 (hu) | 1994-03-17 | 2002-07-29 | Merck Patent Gmbh. | Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok |
| PT1256576E (pt) | 2000-02-15 | 2005-09-30 | Astellas Pharma Inc | Derivados de imidazolio fundidos |
| WO2002066058A1 (en) | 2001-02-19 | 2002-08-29 | Merck Patent Gmbh | Modified anti-egfr antibodies with reduced immunogenicity |
| KR100945108B1 (ko) | 2001-06-13 | 2010-03-02 | 젠맵 에이/에스 | 표피 성장 인자 수용체 (egfr)에 대한 인간모노클로날 항체 |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| KR101015034B1 (ko) | 2003-04-15 | 2011-02-16 | 아스텔라스세이야쿠 가부시키가이샤 | 브롬화물 및 이의 결정 |
| AR046639A1 (es) | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
| DE10355904A1 (de) | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| BRPI0509580A (pt) | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
| JPWO2005111213A1 (ja) | 2004-05-18 | 2008-03-27 | 学校法人 久留米大学 | Myc標的遺伝子mimitin |
| US20060079494A1 (en) | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
| JP2009515878A (ja) | 2005-11-12 | 2009-04-16 | イーライ リリー アンド カンパニー | 抗egfr抗体 |
| JP4806776B2 (ja) | 2006-01-27 | 2011-11-02 | 国立大学法人 千葉大学 | c−myc遺伝子転写抑制因子FIRのスプライシングバリアント又はイントロン2内の4塩基繰り返し配列による癌検出方法 |
| US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| EP2055304A1 (en) | 2006-08-25 | 2009-05-06 | Astellas Pharma Inc. | Stabilized pharmaceutical composition |
| US8227605B2 (en) | 2006-10-31 | 2012-07-24 | Schering Corporation | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| US7618992B2 (en) | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
| CA2703979A1 (en) | 2007-10-29 | 2009-05-07 | Schering Corporation | Heterocyclic ether and thioether derivatives and methods of use thereof |
| US8022057B2 (en) | 2007-11-12 | 2011-09-20 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
| WO2009146034A2 (en) | 2008-03-31 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| AU2009284098B2 (en) | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| WO2010056931A1 (en) | 2008-11-14 | 2010-05-20 | Intelligent Oncotherapeutics, Inc. | Methods for identification of tumor phenotype and treatment |
| US8710068B2 (en) | 2009-01-19 | 2014-04-29 | The Trustees Of The University Of Pennsylvania | Method of treating cancer using a survivin inhibitor |
| CA2789696C (en) * | 2010-02-25 | 2017-11-07 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| US20130035336A1 (en) | 2010-04-13 | 2013-02-07 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer |
| JP2014156400A (ja) | 2011-05-24 | 2014-08-28 | Astellas Pharma Inc | 腫瘍の画像診断用標識誘導体 |
| WO2012167099A1 (en) | 2011-06-01 | 2012-12-06 | Baylor College Of Medicine | Biomarkers and therapy for cancer |
| FI20115876A0 (fi) | 2011-09-06 | 2011-09-06 | Turun Yliopisto | Yhdistelmähoito |
| US20130122005A1 (en) * | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
| RU2014122048A (ru) | 2011-11-16 | 2015-12-27 | Онкомед Фармасьютикалс, Инк. | Мутации рецептора notch человека и их применение |
| WO2013148649A1 (en) | 2012-03-26 | 2013-10-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of survivin antagonists in polyomavirus-related disease |
| EP2945628B1 (en) | 2013-01-15 | 2020-04-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer |
| WO2014152358A2 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
| US20160024591A1 (en) | 2013-03-14 | 2016-01-28 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer |
| MX2015011444A (es) | 2013-03-15 | 2015-12-16 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico. |
| US9913844B2 (en) | 2013-03-21 | 2018-03-13 | Novartis Ag | Combination therapy |
| US9314460B1 (en) | 2013-04-09 | 2016-04-19 | Stc.Unm | Method for cancer cell reprogramming |
| KR101514877B1 (ko) | 2013-05-06 | 2015-04-24 | 조선대학교산학협력단 | APE/Ref -1 및 JAG1/Notch의 대장암 진단용 마커로서의 용도 |
| US20170080093A1 (en) | 2013-10-22 | 2017-03-23 | Tyme, Inc. | Tyrosine Derivatives And Compositions Comprising Them |
| BR112016014481B1 (pt) * | 2013-12-20 | 2022-11-08 | Biomed Valley Discoveries, Inc | Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit |
| US20200237758A1 (en) | 2014-04-04 | 2020-07-30 | Astrazeneca Ab | Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer |
| EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| SG11201610534UA (en) * | 2014-06-16 | 2017-01-27 | Worldwide Innovative Network | Method for selecting personalized tri-therapy for cancer treatment |
| CN107073132B (zh) | 2014-10-06 | 2021-08-27 | 梅约医学教育与研究基金会 | 载体-抗体组合物及其制备和使用方法 |
| BR112017025045A2 (pt) | 2015-05-22 | 2018-08-07 | Plexxikon Inc | plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600 |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| WO2017019279A1 (en) | 2015-07-27 | 2017-02-02 | Southern Research Institute | Methods and compositions to treat cancers involving egfr |
| US20180243304A1 (en) | 2015-08-28 | 2018-08-30 | Novartis Ag | Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer |
| AU2016315878A1 (en) | 2015-09-03 | 2018-03-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| EP3349774A4 (en) | 2015-09-15 | 2019-03-27 | Swedish Health Services | METHOD AND COMPOSITE SHEETS FOR CHARACTERIZING GLOBALBLASTOMA MULTIFORM TUMORS AND CANCER STEM CELLS THEREOF |
| WO2017070475A1 (en) | 2015-10-22 | 2017-04-27 | Merrimack Pharmaceuticals, Inc. | Methods of treating cancer by administering a mek inhibitor and a combination of anti-egfr antibodies |
| AU2017205478A1 (en) | 2016-01-07 | 2018-06-28 | Swadesh K. Das | A method of modulating survival and stemness of cancer stem cells by MDA-9/Syntenin (SDCBP) |
| WO2017143237A1 (en) | 2016-02-17 | 2017-08-24 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs |
| TW201813644A (zh) * | 2016-09-23 | 2018-04-16 | 江蘇恆瑞醫藥股份有限公司 | 酪胺酸激酶抑制劑在製備治療癌症藥物中的用途 |
| WO2018127786A1 (en) | 2017-01-06 | 2018-07-12 | Oslo Universitetssykehus Hf | Compositions and methods for determining a treatment course of action |
| CN106822905B (zh) | 2017-03-08 | 2019-05-17 | 暨南大学 | 含Survivin抑制剂和IRE1抑制剂的药物及用途 |
| WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| US12571049B2 (en) | 2018-03-21 | 2026-03-10 | Dana-Farber Cancer Institute, Inc. | Therapeutic treatment of select diffuse large B cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes |
| WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| WO2020034061A1 (en) | 2018-08-13 | 2020-02-20 | Beijing Percans Oncology Co., Ltd. | Biomarkers for cancer therapy |
| WO2020036852A1 (en) | 2018-08-13 | 2020-02-20 | Beijing Percans Oncology Co. Ltd. | Biomarkers for cancer therapy |
| WO2020097901A1 (en) | 2018-11-16 | 2020-05-22 | Beijing Percans Oncology Co. Ltd. | Biomarkers for cancer therapy |
-
2018
- 2018-04-08 WO PCT/CN2018/082191 patent/WO2019195959A1/en not_active Ceased
-
2019
- 2019-04-08 WO PCT/CN2019/081674 patent/WO2019196764A1/en not_active Ceased
- 2019-04-08 AU AU2019251124A patent/AU2019251124B2/en active Active
- 2019-04-08 CN CN202511418963.8A patent/CN121313846A/zh active Pending
- 2019-04-08 CN CN201980037730.XA patent/CN112566660B/zh active Active
- 2019-04-08 US US17/045,982 patent/US11753476B2/en active Active
- 2019-04-08 JP JP2021503193A patent/JP2021520406A/ja active Pending
- 2019-04-08 EP EP19784395.6A patent/EP3773719A4/en not_active Withdrawn
-
2023
- 2023-07-24 US US18/357,945 patent/US20240059778A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013537544A (ja) * | 2010-08-17 | 2013-10-03 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗癌剤併用療法 |
| WO2012095505A1 (en) * | 2011-01-12 | 2012-07-19 | Boehringer Ingelheim International Gmbh | Anticancer therapy with dual aurora kinase / mek inhibitors |
| JP2015523397A (ja) * | 2012-07-26 | 2015-08-13 | ノバルティス アーゲー | Cdk4/6阻害剤およびb−raf阻害剤の組合せ医薬 |
| JP2017502013A (ja) * | 2013-12-20 | 2017-01-19 | バイオメッド バレー ディスカバリーズ,インコーポレイティド | Cdk阻害剤およびerk阻害剤の組み合わせを使用するがん処置 |
Non-Patent Citations (1)
| Title |
|---|
| CLINICAL CANCER RESEARCH, vol. 20, no. 14, JPN6023015780, 2014, pages 3775 - 3786, ISSN: 0005197821 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024516828A (ja) * | 2021-04-30 | 2024-04-17 | シティ・オブ・ホープ | がん治療のためのpcna阻害剤及びegfr阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019196764A1 (en) | 2019-10-17 |
| EP3773719A4 (en) | 2022-03-02 |
| US20210179718A1 (en) | 2021-06-17 |
| EP3773719A1 (en) | 2021-02-17 |
| US11753476B2 (en) | 2023-09-12 |
| CN112566660B (zh) | 2025-10-21 |
| AU2019251124A1 (en) | 2020-10-22 |
| AU2019251124B2 (en) | 2026-01-08 |
| CN121313846A (zh) | 2026-01-13 |
| WO2019195959A1 (en) | 2019-10-17 |
| CN112566660A (zh) | 2021-03-26 |
| US20240059778A1 (en) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240059778A1 (en) | Combination therapy for cancers with braf mutation | |
| JP6742391B2 (ja) | 併用療法 | |
| AU2013299841B8 (en) | Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor | |
| JP2023145689A (ja) | Her2陽性がんの処置 | |
| TW202342047A (zh) | 使用經取代之嘧啶-4(3h)-酮及索托拉西布(sotorasib)之組合療法 | |
| US20240058339A1 (en) | Combination therapy for cancers with kras mutation | |
| WO2021068867A1 (en) | Combination therapy for cancers with kras mutation | |
| HK40018197A (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| HK1204976B (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220407 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220407 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230421 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231115 |